I. Kinghorn

Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.

P. Harrigan, B. Larder, S. Bruisten, 1997, AIDS research and human retroviruses.

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

P. Harrigan, B. Larder, S. Kemp, 1996, Journal of virology.

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

J W Mulder, R. Schooley, P. Harrigan, 1996, The Journal of infectious diseases.